HUP0003260A3 - Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin - Google Patents

Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin

Info

Publication number
HUP0003260A3
HUP0003260A3 HU0003260A HUP0003260A HUP0003260A3 HU P0003260 A3 HUP0003260 A3 HU P0003260A3 HU 0003260 A HU0003260 A HU 0003260A HU P0003260 A HUP0003260 A HU P0003260A HU P0003260 A3 HUP0003260 A3 HU P0003260A3
Authority
HU
Hungary
Prior art keywords
rosiglitazone
insulin
diabetes
treatment
pharmaceutical composition
Prior art date
Application number
HU0003260A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of HUP0003260A2 publication Critical patent/HUP0003260A2/hu
Publication of HUP0003260A3 publication Critical patent/HUP0003260A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HU0003260A 1997-06-18 1998-06-15 Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin HUP0003260A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (2)

Publication Number Publication Date
HUP0003260A2 HUP0003260A2 (hu) 2001-05-28
HUP0003260A3 true HUP0003260A3 (en) 2001-12-28

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003260A HUP0003260A3 (en) 1997-06-18 1998-06-15 Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin

Country Status (30)

Country Link
EP (1) EP0999837A1 (xx)
JP (1) JP2002504138A (xx)
KR (1) KR20010013843A (xx)
CN (1) CN1133431C (xx)
AP (1) AP1287A (xx)
AR (2) AR015894A1 (xx)
AU (1) AU8216398A (xx)
BG (1) BG104059A (xx)
BR (1) BR9810444A (xx)
CA (1) CA2294141A1 (xx)
CO (1) CO4940454A1 (xx)
DZ (1) DZ2521A1 (xx)
EA (1) EA004800B1 (xx)
GB (1) GB9712866D0 (xx)
HU (1) HUP0003260A3 (xx)
ID (1) ID23951A (xx)
IL (1) IL133143A0 (xx)
IN (1) IN189723B (xx)
MA (1) MA26511A1 (xx)
NO (1) NO996265L (xx)
OA (1) OA11517A (xx)
PE (1) PE104499A1 (xx)
PL (1) PL343123A1 (xx)
SK (1) SK179399A3 (xx)
TR (1) TR199903095T2 (xx)
TW (1) TW587937B (xx)
UA (1) UA70299C2 (xx)
UY (1) UY25050A1 (xx)
WO (1) WO1998057636A1 (xx)
ZA (1) ZA985237B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
DK1133312T3 (da) * 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
BR0316091A (pt) * 2002-11-08 2005-09-27 Hoffmann La Roche Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228260B1 (en) * 1993-09-15 2013-02-28 Daiichi Sankyo Company Pharmaceutical compositions to treat impaired glucose tolerance
CN1192683A (zh) * 1995-08-10 1998-09-09 沃尼尔·朗伯公司 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister

Also Published As

Publication number Publication date
AP9901718A0 (en) 1999-12-31
PE104499A1 (es) 2000-01-13
CN1260715A (zh) 2000-07-19
IN189723B (xx) 2003-04-19
AR015894A1 (es) 2001-05-30
CN1133431C (zh) 2004-01-07
KR20010013843A (ko) 2001-02-26
OA11517A (en) 2004-02-04
IL133143A0 (en) 2001-03-19
AR012997A1 (es) 2000-11-22
MA26511A1 (fr) 2004-12-20
UA70299C2 (en) 2004-10-15
EA200000042A1 (ru) 2000-08-28
SK179399A3 (en) 2000-11-07
HUP0003260A2 (hu) 2001-05-28
AU8216398A (en) 1999-01-04
ID23951A (id) 2000-06-08
EA004800B1 (ru) 2004-08-26
CO4940454A1 (es) 2000-07-24
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
BR9810444A (pt) 2000-09-05
DZ2521A1 (fr) 2003-02-08
GB9712866D0 (en) 1997-08-20
TW587937B (en) 2004-05-21
BG104059A (en) 2000-10-31
ZA985237B (en) 2000-02-17
CA2294141A1 (en) 1998-12-23
UY25050A1 (es) 2000-09-29
AP1287A (en) 2004-06-26
NO996265D0 (no) 1999-12-17
WO1998057636A1 (en) 1998-12-23
NO996265L (no) 1999-12-17
PL343123A1 (en) 2001-07-30
TR199903095T2 (xx) 2000-08-21

Similar Documents

Publication Publication Date Title
AP9901719A0 (en) Treatment of diabetes with thiazolidinedione and metormin
HK1045111A1 (en) (3-Trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin reisistance and type 2 diabetes
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
HK1041203A1 (en) Pharmaceutical composition comprising pioglitazone and glimepiride for use in treatment of diabetes
IL131130A0 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
PL341592A1 (en) Method of administering human aspb28 insulin
IL127219A0 (en) The use of insulin sensitivity enhancers for treatment of hyperuricemia and compositions containing insulin sensitivity enhancers for treating the same
HUP0003260A3 (en) Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
AP2000001733A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and diguanide
EG21712A (en) Treatment of insulin resistance
ZA98647B (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
IL125820A0 (en) Therapeutic agent for diabetes and a pharmaceutical composition containing the same
HUP0003626A3 (en) Pharmaceutical composition for treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
AP2000001734A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1028200A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL133138A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
AU4107797A (en) Compounds for the treatment and prevention of diabetes
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
PH27501A (en) Pharmaceutical formulation and method for the treatment of diabetes mellitus
IL119526A0 (en) Preparations comprising T cells for prevention or treatment of insulin dependent diabetes mellitus (IDDM)
AU6984698A (en) Treatment for insulin dependent diabetes